NASDAQ:TOI

Oncology Institute (TOI) Stock Price, News & Analysis

$1.18
+0.05 (+4.42%)
(As of 04/23/2024 ET)
Today's Range
$1.13
$1.22
50-Day Range
$1.13
$1.95
52-Week Range
$0.33
$2.66
Volume
61,406 shs
Average Volume
125,891 shs
Market Capitalization
$87.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.25

Oncology Institute MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
90.7% Upside
$2.25 Price Target
Short Interest
Healthy
0.84% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.67mentions of Oncology Institute in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$90,550 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.36) to ($0.17) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.72 out of 5 stars

Medical Sector

613th out of 909 stocks

Offices & Clinics Of Medical Doctors Industry

4th out of 7 stocks

TOI stock logo

About Oncology Institute Stock (NASDAQ:TOI)

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.

TOI Stock Price History

TOI Stock News Headlines

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Topicus.com Inc. Announces Release Date for First Quarter Results
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Are we over-looking elderly loneliness?
Q4 2023 Oncology Institute Inc Earnings Call
Recap: Oncology Institute Q4 Earnings
PCOM, The Wistar Institute Announce Cancer Biology Graduate Program
See More Headlines
Receive TOI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncology Institute and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/27/2024
Today
4/23/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Offices & clinics of medical doctors
Sub-Industry
N/A
Current Symbol
NASDAQ:TOI
Fax
N/A
Employees
800
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.25
High Stock Price Target
$2.50
Low Stock Price Target
$2.00
Potential Upside/Downside
+90.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-83,070,000.00
Pretax Margin
-25.63%

Debt

Sales & Book Value

Annual Sales
$324.24 million
Book Value
$0.77 per share

Miscellaneous

Free Float
64,578,000
Market Cap
$87.69 million
Optionable
Not Optionable
Beta
0.68
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Richard Alan Barasch (Age 70)
    Executive Chairman of the Board
  • Dr. Daniel Virnich FACHE (Age 45)
    M.D., MBA, Chief Executive Officer
    Comp: $606.08k
  • Mr. Mihir Arunkumar Shah CPA (Age 46)
    Chief Financial Officer & Principal Accounting Officer
    Comp: $393.65k
  • Ms. Hilda Agajanian M.B.A.
    Founder & Chief Growth Officer
  • Dr. Richy Agajanian M.D.
    Founder & Chief Clinical Officer
  • Mr. Jeremy N. Castle M.B.A. (Age 40)
    Chief Operations Officer
  • Mr. Rakesh Singh M.B.A.
    Director of Technology
  • Mr. Mark Hueppelsheuser Esq.
    General Counsel
  • Mr. Khurrum Shah J.D.
    M.B.A., Senior Vice President of Compliance
  • Ms. Julie Korinke
    Director of Marketing & Communications

TOI Stock Analysis - Frequently Asked Questions

Should I buy or sell Oncology Institute stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncology Institute in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" TOI shares.
View TOI analyst ratings
or view top-rated stocks.

What is Oncology Institute's stock price target for 2024?

1 equities research analysts have issued twelve-month price objectives for Oncology Institute's shares. Their TOI share price targets range from $2.00 to $2.50. On average, they expect the company's share price to reach $2.25 in the next twelve months. This suggests a possible upside of 90.7% from the stock's current price.
View analysts price targets for TOI
or view top-rated stocks among Wall Street analysts.

How have TOI shares performed in 2024?

Oncology Institute's stock was trading at $2.04 at the beginning of the year. Since then, TOI shares have decreased by 42.2% and is now trading at $1.18.
View the best growth stocks for 2024 here
.

When is Oncology Institute's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our TOI earnings forecast
.

How were Oncology Institute's earnings last quarter?

The Oncology Institute, Inc. (NASDAQ:TOI) announced its earnings results on Wednesday, March, 27th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.10. The business earned $85.79 million during the quarter, compared to the consensus estimate of $82.04 million. Oncology Institute had a negative net margin of 24.56% and a negative trailing twelve-month return on equity of 80.46%.

What guidance has Oncology Institute issued on next quarter's earnings?

Oncology Institute updated its FY 2024 earnings guidance on Wednesday, March, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $400.0 million-$415.0 million, compared to the consensus revenue estimate of $378.8 million.

Who are Oncology Institute's major shareholders?

Oncology Institute's stock is owned by a variety of institutional and retail investors. Top institutional investors include Quattro Financial Advisors LLC (0.08%). Insiders that own company stock include Brad Hively, Havencrest Healthcare Partners, Matthew P Miller, Mohit Kaushal, Richard A Barasch and Richy Agajanian.
View institutional ownership trends
.

How do I buy shares of Oncology Institute?

Shares of TOI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TOI) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners